Omeprazole/sodium bicarbonate powder suspension - Salix Pharmaceuticals

Drug Profile

Omeprazole/sodium bicarbonate powder suspension - Salix Pharmaceuticals

Alternative Names: Acitrel; Omez Insta; Rapinex Powder for Oral Suspension; SAN 05; Zegerid Powder for Oral Suspension

Latest Information Update: 07 Apr 2015

Price : $50

At a glance

  • Originator Santarus
  • Developer Norgine; Salix Pharmaceuticals
  • Class Antiulcers; Gastric antisecretories
  • Mechanism of Action Antacids; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Duodenal ulcer; Erosive oesophagitis; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Gastrointestinal haemorrhage

Most Recent Events

  • 01 Apr 2015 Salix Pharmaceuticals has been acquired by Valeant Pharmaceuticals International
  • 02 Jan 2014 Santarus has been acquired and merged into Salix Pharmaceuticals
  • 01 Feb 2011 Norgine completes a Phase-I trial in Duodenal ulcer, Erosive oesophagitis and Gastro-oesophageal reflux (in volunteers) in United Kingdom (NCT01710995)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top